Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Emilie, D; Burgard, M; Lascoux-Combe, C; Laughlin, M; Krzysiek, R; Pignon, C; Rudent, A; Molina, JM; Livrozet, JM; Souala, F; Chene, G; Grangeot-Keros, L; Galanaud, P; Sereni, D; Rouzioux, C
   Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study
   AIDS
   
   D. Emilie et al., "Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study", AIDS, 15(11), 2001, pp. 1435-1437
2. Pellet, C; Chevret, S; Blum, L; Gauville, C; Hurault, M; Blanchard, G; Agbalika, F; Lascoux, C; Ponscarme, D; Morel, P; Calvo, F; Lebbe, C
   Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy
   JOURNAL OF INVESTIGATIVE DERMATOLOGY
   
   C. Pellet et al., "Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy", J INVES DER, 117(4), 2001, pp. 858-863
3. Sereni, D; Tubiana, R; Lascoux, C; Katlama, C; Taulera, O; Bourque, A; Cohen, A; Dvorchik, B; Martin, RR; Tournerie, C; Gouyette, A; Schechter, PJ
   Pharmacokinetics and tolerability of intravenous Trecovirsen (GEM (R) 91),an antisense phosphorothioate oligonucleotide, in HIV-positive subjects
   JOURNAL OF CLINICAL PHARMACOLOGY
   
   D. Sereni et al., "Pharmacokinetics and tolerability of intravenous Trecovirsen (GEM (R) 91),an antisense phosphorothioate oligonucleotide, in HIV-positive subjects", J CLIN PHAR, 39(1), 1999, pp. 47-54
4. Hoen, B; Dumon, B; Harzic, M; Venet, A; Dubeaux, B; Lascoux, C; Bourezane, Y; Ragnaud, JM; Bicart-See, A; Raffi, F; Beauvais, L; Fleury, H; Sereni, D
   Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: Results of the ANRS 053 trial
   JOURNAL OF INFECTIOUS DISEASES
   
   B. Hoen et al., "Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: Results of the ANRS 053 trial", J INFEC DIS, 180(4), 1999, pp. 1342-1346
5. SERENI D; LASCOUX C; GOMEZ V
   NONNUCLEOSIDE RETROVIRUS INHIBITORS
   La Presse medicale
   
   D. Sereni et al., "NONNUCLEOSIDE RETROVIRUS INHIBITORS", La Presse medicale, 25(8), 1996, pp. 361